Drugs / G-Pen
last change May 2018 re-read 2 minutes ago

G-Pen

Developed for
hypoglycemia
Investigated by
Integrated Medical Development · SGS S.A. · Xeris Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03439072 Jan → Apr 2018 hypoglycemia, type 1 diabetes mellitus Xeris Pharmaceuticals Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as G-Pen ClinicalTrials.gov intervention name — accepted as the source's own label NCT03439072
Route Subcutaneous “1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector” NCT03439072